Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: an example from the Canadian Cancer Trials Group CO.17 trial

Peer Review reports

Original Submission
11 Dec 2018	Submitted	Original manuscript
27 Jan 2019	Reviewed	Reviewer Report - Hideki Hashimoto
21 Feb 2019	Reviewed	Reviewer Report - Felix Achana
12 Apr 2019	Author responded	Author comments - Jeffrey Hoch
Resubmission - Version 2
12 Apr 2019	Submitted	Manuscript version 2
15 Apr 2019	Reviewed	Reviewer Report - Hideki Hashimoto
8 May 2019	Reviewed	Reviewer Report - Felix Achana
26 May 2019	Author responded	Author comments - Jeffrey Hoch
Resubmission - Version 3
26 May 2019	Submitted	Manuscript version 3
Publishing
31 May 2019	Editorially accepted
7 Jun 2019	Article published	10.1186/s12885-019-5779-x

Back to article page